Odevixibat gains FDA nod for rare liver disease PFIC
2021-07-27
Albireo Pharma's Bylvay, or odevixibat, gained the FDA's approval to treat pruritus for patients ages 3 months and older who have progressive familial intrahepatic cholestasis. Approval of the oral reversible inhibitor was backed by results from two late-stage studies.
Full story: 
AIChE SmartBrief
Chemical engineering news
Designed specifically for chemical engineers, AIChE SmartBrief is a FREE weekly email newsletter. It helps chemical engineers stay informed on the business and technology developments affecting our profession.